Estimates of Incidence and Predictors of Fatiguing Illness after SARS-CoV-2 Infection
This study aimed to estimate the incidence rates of post-COVID-19 fatigue and chronic fatigue and to quantify the additional incident fatigue caused by COVID-19. We analyzed electronic health records data of 4,589 patients with confirmed COVID-19 during February 2020-February 2021 who were followed for a median of 11.4 (interquartile range 7.8-15.5) months and compared them to data from 9,022 propensity score-matched non-COVID-19 controls. Among COVID-19 patients (15% hospitalized for acute COVID-19), the incidence rate of fatigue was 10.2/100 person-years and the rate of chronic fatigue was 1.8/100 person-years. Compared with non-COVID-19 controls, the hazard ratios were 1.68 (95% CI 1.48-1.92) for fatigue and 4.32 (95% CI 2.90-6.43) for chronic fatigue. The observed association between COVID-19 and the significant increase in the incidence of fatigue and chronic fatigue reinforces the need for public health actions to prevent SARS-CoV-2 infections.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
---|---|
Enthalten in: |
Emerging infectious diseases - 30(2024), 3 vom: 15. März, Seite 539-547 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Vu, Quan M [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 27.02.2024 Date Revised 02.03.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.3201/eid3003.231194 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368971406 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368971406 | ||
003 | DE-627 | ||
005 | 20240302232624.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240229s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3201/eid3003.231194 |2 doi | |
028 | 5 | 2 | |a pubmed24n1314.xml |
035 | |a (DE-627)NLM368971406 | ||
035 | |a (NLM)38407166 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Vu, Quan M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Estimates of Incidence and Predictors of Fatiguing Illness after SARS-CoV-2 Infection |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.02.2024 | ||
500 | |a Date Revised 02.03.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a This study aimed to estimate the incidence rates of post-COVID-19 fatigue and chronic fatigue and to quantify the additional incident fatigue caused by COVID-19. We analyzed electronic health records data of 4,589 patients with confirmed COVID-19 during February 2020-February 2021 who were followed for a median of 11.4 (interquartile range 7.8-15.5) months and compared them to data from 9,022 propensity score-matched non-COVID-19 controls. Among COVID-19 patients (15% hospitalized for acute COVID-19), the incidence rate of fatigue was 10.2/100 person-years and the rate of chronic fatigue was 1.8/100 person-years. Compared with non-COVID-19 controls, the hazard ratios were 1.68 (95% CI 1.48-1.92) for fatigue and 4.32 (95% CI 2.90-6.43) for chronic fatigue. The observed association between COVID-19 and the significant increase in the incidence of fatigue and chronic fatigue reinforces the need for public health actions to prevent SARS-CoV-2 infections | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a ME/CFS | |
650 | 4 | |a PASC | |
650 | 4 | |a PCC | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a coronavirus disease 2019 | |
650 | 4 | |a fatigue | |
650 | 4 | |a incidence | |
650 | 4 | |a myalgic encephalomyelitis/chronic fatigue syndrome | |
650 | 4 | |a post COVID-19 conditions | |
650 | 4 | |a post-acute sequelae of SARS-CoV-2 infection | |
650 | 4 | |a respiratory infections | |
650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
650 | 4 | |a viruses | |
650 | 4 | |a zoonoses | |
700 | 1 | |a Fitzpatrick, Annette L |e verfasserin |4 aut | |
700 | 1 | |a Cope, Jennifer R |e verfasserin |4 aut | |
700 | 1 | |a Bertolli, Jeanne |e verfasserin |4 aut | |
700 | 1 | |a Sotoodehnia, Nona |e verfasserin |4 aut | |
700 | 1 | |a West, T Eoin |e verfasserin |4 aut | |
700 | 1 | |a Gentile, Nikki |e verfasserin |4 aut | |
700 | 1 | |a Unger, Elizabeth R |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 30(2024), 3 vom: 15. März, Seite 539-547 |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
773 | 1 | 8 | |g volume:30 |g year:2024 |g number:3 |g day:15 |g month:03 |g pages:539-547 |
856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid3003.231194 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 30 |j 2024 |e 3 |b 15 |c 03 |h 539-547 |